IgA nephropathy, susceptibility to, 1
diseaseOn this page
Also known as glomerulonephritis, IgAIGAN1
Summary
IgA nephropathy, susceptibility to, 1 (MONDO:0008072) is a disease and 20 clinical trials. Top therapeutic interventions include aliskiren, cilazapril, and iptacopan. A subtype of IgA nephropathy, susceptibility to — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 20
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | IgA nephropathy, susceptibility to, 1 |
| Mondo ID | MONDO:0008072 |
| OMIM | 161950 |
| UMLS | C3160719 |
| MedGen | 463619 |
| Is cancer (heuristic) | no |
Also known as: glomerulonephritis, IgA · IgA nephropathy, susceptibility to, 1 · IGAN1
Disease family
This is a subtype of IgA nephropathy, susceptibility to. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease susceptibility › inherited disease susceptibility › IgA nephropathy, susceptibility to › IgA nephropathy, susceptibility to, 1
Related subtypes (2): IgA nephropathy, susceptibility to, 2, IgA nephropathy, susceptibility to, 3
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 20.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| Not specified | 6 |
| PHASE4 | 3 |
| PHASE3 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06528015 | PHASE4 | NOT_YET_RECRUITING | Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy |
| NCT01184599 | PHASE4 | UNKNOWN | A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy |
| NCT04020328 | PHASE4 | UNKNOWN | Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency |
| NCT05510323 | PHASE3 | RECRUITING | Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD |
| NCT06858319 | PHASE3 | RECRUITING | Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. |
| NCT02232776 | PHASE3 | COMPLETED | Efficacy and Safety of Losartan in Children With Ig A Nephropathy |
| NCT02647255 | PHASE2/PHASE3 | TERMINATED | Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy |
| NCT04663204 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy |
| NCT06797518 | PHASE2 | RECRUITING | Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN |
| NCT00396721 | PHASE2 | COMPLETED | Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy |
| NCT00446251 | PHASE2 | COMPLETED | Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant |
| NCT00446459 | PHASE2 | COMPLETED | Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. |
| NCT02160132 | PHASE2 | UNKNOWN | A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. |
| NCT03841448 | PHASE2 | TERMINATED | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) |
| NCT01802034 | Not specified | RECRUITING | Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) |
| NCT05791162 | Not specified | RECRUITING | Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy |
| NCT00378443 | Not specified | UNKNOWN | ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT |
| NCT00521508 | Not specified | COMPLETED | Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy |
| NCT04092491 | Not specified | UNKNOWN | Study of the IgA Repertoire During IgA Deposition Nephropathy. |
| NCT05797051 | Not specified | UNKNOWN | Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ALISKIREN | 4 | 1 |
| CILAZAPRIL | 4 | 1 |
| IPTACOPAN | 4 | 1 |
| LEFLUNOMIDE | 4 | 1 |
| SPARSENTAN | 4 | 1 |
| CEMDISIRAN | 3 | 1 |
| ZIGAKIBART | 3 | 1 |
Related Atlas pages
- Drugs: Aliskiren, Cilazapril, Iptacopan, Leflunomide, Sparsentan, Cemdisiran, Zigakibart